0001974158-24-000010.txt : 20240227
0001974158-24-000010.hdr.sgml : 20240227
20240227160205
ACCESSION NUMBER: 0001974158-24-000010
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 24686356
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Hohl Benjamin
CENTRAL INDEX KEY: 0001882764
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
144
1
primary_doc.xml
144
0001882764
XXXXXXXX
LIVE
0001672619
Enliven Therapeutics, Inc.
001-39247
6200 LOOKOUT ROAD
BOULDER
CO
80301
720-647-8519
Hohl Benjamin
Officer
Common
Jefferies LLC
520 Madison Ave
4th Fl
New York
NY
10022
16250
285350.00
41000000
02/27/2024
NASDAQ
Common
08/09/2022
Stock Option Grant
Enliven Therapeutics, Inc.
N
16250
08/09/2022
N/A
N
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
12/27/2023
1030
15524.94
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
12/27/2023
100
1500.00
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
12/28/2023
2467
37188.03
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
12/29/2023
20
300.00
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
01/02/2024
9383
140838.64
Benjamin Hohl
6200 Lookout Rd 1st Fl
Boulder
CO
80301
Enliven Therapeutics
01/29/2024
3250
51388.51
All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 06/26/2023, and all representations regarding material non-public information were made as of the adoption of the plan.
02/27/2024
06/26/2023
Benjamin Hohl